Literature DB >> 16610769

HuCNS-SC (StemCells).

Philippe Taupin1.   

Abstract

HuCNS-SC, a proprietary human neural stem cells product, is being developed as a cellular therapy for the potential treatment of Batten disease, one of a group of disorders known as neural ceroid lipofuscinoses (NCL). Developer StemCells is also investigating the therapy for spinal cord injury and other central nervous system disorders, such as demyelinating disease, stroke and Alzheimer's disease. A phase I trial of HuCNS-SC for infantile and late-infantile NCL has been initiated, following the March 2006 U.S. Food and Drug Administration approval of StemCells' investigational new drug application.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16610769

Source DB:  PubMed          Journal:  Curr Opin Mol Ther        ISSN: 1464-8431


  13 in total

1.  Differential pathotropism of non-immortalized and immortalized human neural stem cell lines in a focal demyelination model.

Authors:  Daniela Ferrari; Cristina Zalfa; Laura Rota Nodari; Maurizio Gelati; Luigi Carlessi; Domenico Delia; Angelo Luigi Vescovi; Lidia De Filippis
Journal:  Cell Mol Life Sci       Date:  2011-11-11       Impact factor: 9.261

2.  Human induced pluripotent stem cells are a novel source of neural progenitor cells (iNPCs) that migrate and integrate in the rodent spinal cord.

Authors:  Dhruv Sareen; Geneviève Gowing; Anais Sahabian; Kevin Staggenborg; Renée Paradis; Pablo Avalos; Jessica Latter; Loren Ornelas; Leslie Garcia; Clive N Svendsen
Journal:  J Comp Neurol       Date:  2014-04-12       Impact factor: 3.215

Review 3.  Neural stem cell transplantation as a therapeutic approach for treating lysosomal storage diseases.

Authors:  Lamya S Shihabuddin; Seng H Cheng
Journal:  Neurotherapeutics       Date:  2011-10       Impact factor: 7.620

4.  Residual levels of tripeptidyl-peptidase I activity dramatically ameliorate disease in late-infantile neuronal ceroid lipofuscinosis.

Authors:  David E Sleat; Mukarram El-Banna; Istvan Sohar; Kwi-Hye Kim; Kostantin Dobrenis; Steven U Walkley; Peter Lobel
Journal:  Mol Genet Metab       Date:  2008-03-17       Impact factor: 4.797

Review 5.  The role of animal models in evaluating reasonable safety and efficacy for human trials of cell-based interventions for neurologic conditions.

Authors:  Alan Regenberg; Debra J H Mathews; David M Blass; Hilary Bok; Joseph T Coyle; Patrick Duggan; Ruth Faden; Julia Finkel; John D Gearhart; Argye Hillis; Ahmet Hoke; Richard Johnson; Michael Johnston; Jeffrey Kahn; Douglas Kerr; Patricia King; Joanne Kurtzberg; S Matthew Liao; John W McDonald; Guy McKhann; Karin B Nelson; Mahendra Rao; Andrew W Siegel; Kirby Smith; Davor Solter; Hongjun Song; Jeremy Sugarman; Angelo Vescovi; Wise Young; Henry T Greely; Richard J Traystman
Journal:  J Cereb Blood Flow Metab       Date:  2008-08-27       Impact factor: 6.200

6.  Cerebellar pathology and motor deficits in the palmitoyl protein thioesterase 1-deficient mouse.

Authors:  Shannon L Macauley; David F Wozniak; Catherine Kielar; Yun Tan; Jonathan D Cooper; Mark S Sands
Journal:  Exp Neurol       Date:  2009-02-10       Impact factor: 5.330

Review 7.  Stem cells and neurological diseases.

Authors:  D C Hess; C V Borlongan
Journal:  Cell Prolif       Date:  2008-02       Impact factor: 6.831

Review 8.  Concise review: self-renewal in the central nervous system: neural stem cells from embryo to adult.

Authors:  Lidia De Filippis; Elena Binda
Journal:  Stem Cells Transl Med       Date:  2012-04-10       Impact factor: 6.940

9.  Human recombinant palmitoyl-protein thioesterase-1 (PPT1) for preclinical evaluation of enzyme replacement therapy for infantile neuronal ceroid lipofuscinosis.

Authors:  Jui-Yun Lu; Jie Hu; Sandra L Hofmann
Journal:  Mol Genet Metab       Date:  2009-12-05       Impact factor: 4.797

10.  Chromosome 7 and 19 trisomy in cultured human neural progenitor cells.

Authors:  Dhruv Sareen; Erin McMillan; Allison D Ebert; Brandon C Shelley; Julie A Johnson; Lorraine F Meisner; Clive N Svendsen
Journal:  PLoS One       Date:  2009-10-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.